Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA, Japan), Therapeutic Goods Administration (TGA, Australia), Health Canada, and Medsafe (New Zealand)
Safety and Facts Introduction Managing multiple health goals often means balancing more than one medication at a time
In its first-quarter results update, Novo Nordisk said it has started to see injectable Wegovy users migrate to the high-dose formulation, whilst cautioning it is still too early to call that a definite trend
Leaving the vial out during injection preparation
It was discovered in 2012,[3] by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide.[4] Clinical trials were started in 2015, and phase 3 was completed in 2016.[5] Researchers at the University of Leeds and Novo Nordisk reported in 2017 that it can also be used for the treatment of obesity.[6] It reduces hunger, food craving and body fat.[7] FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour.[8] On December 5, 2017, semaglutide was approved by the US FDA
